Antibodies to vascular endothelial growth factor 2 (VEGF-2)

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S141100, C424S145100

Reexamination Certificate

active

07402312

ABSTRACT:
Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention also relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.

REFERENCES:
patent: 5073492 (1991-12-01), Chen et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5283354 (1994-02-01), Lemischka
patent: 5326695 (1994-07-01), Andersson et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5633147 (1997-05-01), Meissner et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5861301 (1999-01-01), Terman et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7208582 (2007-04-01), Rosen et al.
patent: 7223724 (2007-05-01), Alderson et al.
patent: 7227005 (2007-06-01), Hu et al.
patent: 710696 (1999-09-01), None
patent: 0 476983 (1992-03-01), None
patent: 0-476983 (1992-03-01), None
patent: 0-506477 (1992-09-01), None
patent: WO-92/14748 (1992-09-01), None
patent: WO-95/19985 (1995-07-01), None
patent: WO-95/24414 (1995-09-01), None
patent: WO-95/24473 (1995-12-01), None
patent: WO-96/05856 (1996-02-01), None
patent: WO-96/39515 (1996-12-01), None
patent: WO-97/00271 (1997-01-01), None
patent: WO-97/05250 (1997-02-01), None
patent: WO-97/08320 (1997-03-01), None
patent: WO-97/09427 (1997-03-01), None
patent: WO-97/17442 (1997-05-01), None
patent: WO-97/19694 (1997-06-01), None
patent: WO-98/06844 (1998-02-01), None
patent: WO-98/07832 (1998-02-01), None
patent: WO-98/24811 (1998-06-01), None
patent: WO-98/33917 (1998-06-01), None
patent: WO-98/39035 (1998-09-01), None
patent: WO-98/49300 (1998-11-01), None
patent: WO-98/55619 (1998-12-01), None
patent: WO-98/56936 (1998-12-01), None
patent: WO-99/02545 (1999-01-01), None
patent: WO-99/08522 (1999-02-01), None
patent: WO-99/20749 (1999-04-01), None
patent: WO-99/21590 (1999-05-01), None
patent: WO-99/46364 (1999-09-01), None
patent: WO-00/73430 (2000-12-01), None
patent: WO-00/75163 (2000-12-01), None
patent: WO-01/57226 (2001-08-01), None
patent: WO-01/58956 (2001-08-01), None
patent: 9-403464 (1996-01-01), None
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79(6):1979-1983 (Mar. 1982).
Ngo et al., The Protein Folding Problem and Teriary Structure Prediction, pp. 492-495.
Achen et al., “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4),” Proc. Natl. Acad. Sci. (USA), 95(2): 548-553 (1998).
Alderson, et al. (1999) Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro. Keystone Symposia, Ocular Cell and Molecular Biology, 202. (Abstract provided).
Andersson et al., “Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF,” J. Biol. Chem., 267(16): 11260-11266 (1992).
Andersson W.F., “Human gene therapy,”Science, 256:808-813 (1992).
Aprelikova et al., “FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter,” Cancer Research, 52:746-748 (1992).
Dignam et al., “Balbiani ring 3 inChironomus tentansencodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar,”Gene88:133-140 (1990).
Ferrara et al., “Molecular and biological properties of the vascular endothelial growth factor family of proteins,”Endocrine Rev. 13(l): 18-32 (1992).
Finnerty et al., “Molecular cloning of murine FLT and FLT4,”Oncogene8(11): 2293-2298 (1993).
Heldin et al., “Structure of platelet-derived growth factor: implications for functional properties,”Growth Factors8:245-252 (1993).
Eichmann et al., “Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors,”Development125(4): 743-752 (1998).
Pajusola et al., “FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines,”Cancer Research52:5738-5743 (1992).
Leung et al., “Vascular endothelial growth factor is a secreted angiogenic mitogen,”Science246:1306-1309 (1989).
Breier et al., “Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation,”Development114:521-532 (1992).
Bell et al., “Human epidermal growth factor precuror: cDNA sequence, expression in vitro and gene organization,”Nucl. Acids Res. 14(21): 8427-8446 (1986).
Berse et al., Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors,Mol. Biol. Cell. 3:211-220 (1992).
Betsholtz et al., “cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines,”Nature320:695-699 (1986).
Claffey et al., “Vascular endothelial growth factor,”J. Biol. Chem. 267(23): 16317-16322 (1992).
Corson et al., “Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end,”Genomics17:476-484 (1993).
Ferrara et al., “The vascular endothelial growth factor family of polypeptides,”J. Cellular Biochemistry47:211-218 (1991).
George et al., “Current Methods in Sequence Comparison and Analysis,” Macromolecular Seq. and Syn. Selected Meth—Application (Alan R. Liss), pp. 127-149 (1988).
Hu et al., “A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells,”FASEB J., 11:498-504 (1997).
Joukov et al., “A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases,”EMBO J. 15(2): 290-298 (1996).
Joukov et al., “Proteolytic processing regulates receptor specificity and activity of VEGF-C,”EMBO J. 16(13): 3898-3911 (1997).
Kaipainen et al., “The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells,”J. Exp. Med. 178:2077-2088 (1993).
Keck et al., “Vascular permeability factor, an endothelial cell mitogen related to PDGF,”Science246: 1309 (1989).
Kingsley, D., “The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms,”Genes&Development8: 133-146 (1994).
Kukk et al., “VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development,”Development122: 3829-37 (1996).
Lee et al., “Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4,”Proc. Natl. Acad. Sci.(USA), 93:1988-1992 (1996).
Maglione et al., “Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14,”Oncogene8:925-931 (1993).
Maglione et al., “Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor,”Proc. Natl. Acad. Sci.(USA), 88:9267-9271 (1991).
Massague, J., “The transforming growth factor-beta family,”Annu. Rev. Cell Biol. 6:597-641 (1990).
Matthews et al., “A receptor tyrosine kinase cDNA isolate

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antibodies to vascular endothelial growth factor 2 (VEGF-2) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to vascular endothelial growth factor 2 (VEGF-2), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to vascular endothelial growth factor 2 (VEGF-2) will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2769329

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.